[EN] ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ALLOSTERIC MODULATORS, THEIR DERIVATIVES AND USES THEREOF<br/>[FR] MODULATEURS ALLOSTÉRIQUES DES RÉCEPTEURS NICOTINIQUES DE L'ACÉTYLCHOLINE DE TYPE ALPHA 7, LEURS DÉRIVÉS ET LEURS UTILISATIONS
申请人:ALPHARMAGEN LLC
公开号:WO2016144792A1
公开(公告)日:2016-09-15
The present application is related to compounds represented by Formula I, which are novel positive allosteric modulators of α7 nAChRs. The application also discloses the treatment of disorders that are responsive to enhancement of acetylcholine action on α7 nAChRs in a mammal by administering an effective amount of a compound of Formula I.
HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS
申请人:Hilpert Kurt
公开号:US20140163035A1
公开(公告)日:2014-06-12
The invention relates to heterocyclic amide derivatives of formula (I), wherein R
1
, R
2
, R
3
, R
4
, R
5
, X, Y and n are as defined in the description, their preparation and their use as pharmaceutically active compounds.
[EN] HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS<br/>[FR] DÉRIVÉS D'AMIDES HÉTÉROCYCLIQUES UTILISÉS COMME ANTAGONISTES DU RÉCEPTEUR P2X7
申请人:ACTELION PHARMACEUTICALS LTD
公开号:WO2013014587A1
公开(公告)日:2013-01-31
The invention relates to heterocyclic amide derivatives of formula (I), wherein R1, R2, R3, R4, R5, X, Y and n are as defined in the description, their preparation and their use as pharmaceutically active compounds.
Pyridazine Analogues of Biologically Active Compounds, VI1,2): Pyrido[2,3-c]pyridazines Structurally Related to Nalidixic Acid
作者:Philip Y. Boamah、Norbert Haider、Gottfried Heinisch
DOI:10.1002/ardp.19903230405
日期:——
Synthesis of 8‐alkyl‐5,8‐dihydro‐5‐oxopyrido[2,3‐c]pyridazine‐6‐carboxylic acids 7a–d, starting from 3‐chloro‐4‐pyridazinecarbonitrile, is reported. The novel compounds do not exhibit significant (gyrase‐inhibiting) antibacterial activity.
Compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat, prevent or diagnose diseases, disorders, or conditions associated with one or more of the lysophosphatidic acid receptors are provided.